These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23672094)

  • 41. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F; Park J; Redemann N; Luippold G; Nar H
    J Mol Biol; 2014 Feb; 426(4):843-52. PubMed ID: 24252255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM; Dorsch MP; Bleske BE
    Pharmacotherapy; 2013 Apr; 33(4):447-60. PubMed ID: 23553812
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PCSK9 and lipid lowering drugs.
    Guo YL; Zhang W; Li JJ
    Clin Chim Acta; 2014 Nov; 437():66-71. PubMed ID: 25036764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on the molecular biology of dyslipidemias.
    Ramasamy I
    Clin Chim Acta; 2016 Feb; 454():143-85. PubMed ID: 26546829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progress in finding pathogenic DNA copy number variations in dyslipidemia.
    Iacocca MA; Dron JS; Hegele RA
    Curr Opin Lipidol; 2019 Apr; 30(2):63-70. PubMed ID: 30664016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid metabolism: the significance of plasma proprotein convertase subtilisin kexin type 9 in the elucidation of complex lipid disorders.
    Brouwers MC; van Greevenbroek MM
    Curr Opin Lipidol; 2011 Aug; 22(4):317-8. PubMed ID: 21743308
    [No Abstract]   [Full Text] [Related]  

  • 48. [Targets of anti-hyperlipidemia drugs].
    Li H; Jing X; Deng X; Ouyang D
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jan; 38(1):101-8. PubMed ID: 23406852
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Translating genetic association of lipid levels for biological and clinical application.
    Crone B; Krause AM; Hornsby WE; Willer CJ; Surakka I
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):617-626. PubMed ID: 33604704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetics of Dyslipidemia and Ischemic Heart Disease.
    Sharma K; Baliga RR
    Curr Cardiol Rep; 2017 May; 19(5):46. PubMed ID: 28429242
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proprotein convertase subtilisin/kexin type 9 as transducer of physiologic influences on cellular cholesterol: a case for resistin.
    Fazio S; Linton MF
    J Am Coll Cardiol; 2012 May; 59(19):1706-8. PubMed ID: 22554601
    [No Abstract]   [Full Text] [Related]  

  • 52. Novel Therapeutic Targets for Managing Dyslipidemia.
    Sathiyakumar V; Kapoor K; Jones SR; Banach M; Martin SS; Toth PP
    Trends Pharmacol Sci; 2018 Aug; 39(8):733-747. PubMed ID: 29970260
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetics of cholesterol and lipoprotein metabolism.
    Samuels ME
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):195-204. PubMed ID: 18221119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. From lipid locus to drug target through human genomics.
    van der Laan SW; Harshfield EL; Hemerich D; Stacey D; Wood AM; Asselbergs FW
    Cardiovasc Res; 2018 Jul; 114(9):1258-1270. PubMed ID: 29800275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Perspectives of Genetic Analyses on Dyslipidemia and Coronary Artery Disease.
    Tada H; Kawashiri MA; Yamagishi M
    J Atheroscler Thromb; 2017 May; 24(5):452-461. PubMed ID: 28250266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic susceptibility to cerebrovascular disease.
    Della-Morte D; Pacifici F; Rundek T
    Curr Opin Lipidol; 2016 Apr; 27(2):187-95. PubMed ID: 26959706
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of DNA copy number variation in dyslipidemias.
    Iacocca MA; Hegele RA
    Curr Opin Lipidol; 2018 Apr; 29(2):125-132. PubMed ID: 29303791
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic application of genome editing in dyslipidemia.
    Whittaker MN; Musunuru K
    Curr Opin Lipidol; 2022 Apr; 33(2):133-138. PubMed ID: 34907967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A quantum mechanics-based halogen bonding scoring function for protein-ligand interactions.
    Yang Z; Liu Y; Chen Z; Xu Z; Shi J; Chen K; Zhu W
    J Mol Model; 2015 Jun; 21(6):138. PubMed ID: 25957658
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Genetic predisposition to dyslipidemia].
    Hirayama S; Miida T
    Rinsho Byori; 2013 Feb; 61(2):159-66. PubMed ID: 23672094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.